Rare disease news, mapped to the diseases behind the headlines. AI-classified across pipeline, policy, funding, science, and community.
Be among the first to receive Kisho Intelligence Briefings
Showing news related to
Showing 1–1 of 1 stories
FDA approves Omisirge (omidubicel-onlv), the first cellular therapy for severe aplastic anemia, marking a significant advancement in treatment options for this condition. This approval highlights the potential of hematopoietic stem cell transplants in addressing severe cases of SAA.
Read full storyGet the week's most important rare disease developments — pipeline moves, policy changes, and funding signals — delivered to your inbox every Monday.
Free weekly briefing. Unsubscribe anytime.